InnoCan Pharma Corporation (INNPF)
OTCMKTS · Delayed Price · Currency is USD
0.1608
+0.0058 (3.74%)
Sep 2, 2025, 2:57 PM EDT
InnoCan Pharma Revenue
InnoCan Pharma had revenue of $7.01M in the quarter ending June 30, 2025, a decrease of -18.95%. This brings the company's revenue in the last twelve months to $28.83M, up 18.20% year-over-year. In the year 2024, InnoCan Pharma had annual revenue of $29.44M with 115.55% growth.
Revenue (ttm)
28.83M
Revenue Growth
+18.20%
P/S Ratio
1.62
Revenue / Employee
n/a
Employees
n/a
Market Cap
46.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.44M | 15.78M | 115.55% |
| Dec 31, 2023 | 13.66M | 11.10M | 433.69% |
| Dec 31, 2022 | 2.56M | 2.36M | 1,205.61% |
| Dec 31, 2021 | 196.00K | 188.00K | 2,350.00% |
| Dec 31, 2020 | 8.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 105.45M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Longduoduo Company | 4.99M |
InnoCan Pharma News
- 2 years ago - Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million - GlobeNewsWire
- 2 years ago - Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team - Newsfile Corp
- 2 years ago - Innocan Pharma Announces First Patent Grant in the United States - Newsfile Corp
- 2 years ago - Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial - Newsfile Corp
- 2 years ago - Innocan Pharma Provides Annual "State of the Business" Update - Newsfile Corp
- 2 years ago - Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field - Newsfile Corp
- 3 years ago - Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021 - Newsfile Corp
- 3 years ago - Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee - Newsfile Corp